Amit Bahl

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker, Nicholas D. James, Chris Brawley et al. · The Lancet · 2018 · 1.2K citations · Full text

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

Christopher Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2020 · 386 citations · Full text

Urology, Radiation Medicine, Surgical Oncology +7

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Adrian Murray Brunt, Duncan Wheatley, John Yarnold et al. · Radiotherapy and Oncology · 2016 · 218 citations · Full text

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

M. Bolla, P. Maingon, C. Carrié et al. · Journal of Clinical Oncology · 2016 · 211 citations · Full text

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use

David Lorente, Joaquı́n Mateo, Arnoud J. Templeton et al. · Annals of Oncology · 2014 · 188 citations · Full text

Urology, Baseline Neutrophil–lymphocyte Ratio, Medicine +7